News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nymox Pharmaceutical (NYMX) Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH


4/23/2013 11:17:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the first patient has been enrolled in the Company's Study NX02-0022. The NX02-0022 Study is designed as an open label study of the safety and efficacy of NX-1207 reinjection for the treatment of prostate enlargement (benign prostatic hyperplasia or BPH). The new study will enroll 100-200 subjects who had previously participated in an NX-1207 BPH study and will involve a second treatment of intraprostatic NX-1207 2.5 mg.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES